References
- Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., & Mansoor, L. E. (2010). Effectiveness and safety of Tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 329, 1168–1174. doi:10.1126/science.1193748
- AIDS Healthcare Foundation. (2012). FDA AIDS protest targets approval of Gilead's prevention pill. Retrieved from http://www.aidshealth.org/archives/6488
- Ajzen, I., & Madden, T. J. (1986). Prediction of goal-directed behavior: Attitudes, intentions, and perceived behavioral control. Journal of Experimental Social Psychology, 22, 453–474. doi:10.1016/0022-1031(86)90045-4
- Arnold, E. A., Hazelton, P., Lane, T., Christopoulos, K. A., Galindo, G. R., & Steward, W. T. (2012). A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE, 7, e40603. doi:10.1371/journal.pone.0040603
- Associated Press. (2012). FDA panel backs first pill to block HIV infection. Retrieved from http://www.msnbc.msn.com/id/47386249/ns/health-aids/t/fda-panel-backs-first-pill-block-hiv-infection/#.UNzDCazheSo
- Baeten, J., & Celum, C. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England Journal of Medicine, 367, 399–410. doi:10.1056/NEJMoa1108524
- Bernstein, K. T., Liu, K., Begier, E. M., Koblin, B., Karpati, A., & Murrill, C. (2008). Same-sex attraction disclosure to health care providers among New York City men who have sex with men: Implications for HIV testing approaches. Archives of Internal Medicine, 168, 1458–1464. doi:10.1001/archinte.168.13.1458
- Boldero, J., Sanitioso, R., & Brain, B. (1999). Gay Asian Australians' safer-sex behavior and behavioral skills: The predictive utility of the theory of planned behavior and cultural factors 1. Journal of Applied Social Psychology, 29, 2143–2163. doi:10.1111/j.1559-1816.1999.tb02299.x
- Centers for Disease Control and Prevention (CDC). (2012a). CDC statement on FDA approval of drug for HIV prevention. Retrieved from http://www.cdc.gov/hiv/prep/pdf/CDC_FDA_Approval_Truvada.pdf
- Centers for Disease Control and Prevention (CDC). (2012b). CDC statement on FDA approval of drug for HIV prevention (Press Release). Retrieved from http://www.cdc.gov/hiv/prep/pdf/CDC_FDA_Approval_Truvada.pdf
- DeVellis, R. F. (2003). Scale development: Theory and applications. Thousand Oaks, CA: Sage.
- Epstein, R. M., Morse, D. S., Frankel, R. M., Frarcy, L., Anderson, K., & Beckman, H. B. (1998). Awkward moments in patient–physician communication about HIV risk (Vol. 128). Philadelphia, PA: American College of Physicians.
- Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., … Glidden, D. V. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine, 363, 2587–2599. doi:10.1056/NEJMoa1011205
- Hall, H. I., Song, R., Rhodes, P., Prejean, J., An, Q., & Lee, L. M. (2008). HIV incidence surveillance group: Estimation of HIV incidence in the United States. Journal of the American Medical Association, 300, 520–529. doi:10.1001/jama.300.5.520
- Jolliffe, I. T. (2002). Principal components analysis. New York, NY: Springer.
- Maznavi, K., Hardy, D., & Bredeek, F. (2011). Pre-exposure prophylaxis (PrEP) for HIV: An online survey of HIV healthcare providers evaluating their knowledge, perception, and prescription of PrEP [409]. 49th Annual Meeting of the Infectious Diseases Society of America, Boston.
- Mutua, G., Sanders, E., Mugo, P., Anzala, O., Haberer, J. E., & Bangsberg, D. (2012). Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS ONE, 7, e33103. doi:10.1371/journal.pone.0033103
- Paltiel, A. D., Freedberg, K. A., Scott, C. A., Schackman, B. R., Losina, E., & Wang, B. (2009). HIV preexposure prophylaxis in the United States: Impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clinical Infectious Diseases, 48, 806–815. doi:10.1086/597095
- Petroll, A. E., & Mosack, K. E. (2011). Physician awareness of sexual orientation and preventive health recommendations to men who have sex with men. Sexually Transmitted Diseases, 38(1), 63–67. doi:10.1097/OLQ.0b013e3181ebd50f
- Supervie, V., García-Lerma, J. G., Heneine, W., & Blower, S. (2010). HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proceedings of the National Academy of Sciences, 107, 12381–12386. doi:10.1073/pnas.1006061107
- Susman, E. (2012). Prophylaxis fails to prevent HIV in women. Retrieved from http://www.medpagetoday.com/MeetingCoverage/CROI/31506
- Tripathi, A., Ogbuanu, C., Monger, M., Gibson, J. J., & Duffus, W. A. (2012). Pre-exposure prophylaxis for HIV infection: Healthcare providers' knowledge, perception, and willingness to adopt future implementation in the Southern US. Southern Medical Journal, 105(4), 8. doi:10.1097/SMJ.0b013e31824f1a1b
- Tuller, D. (2011). Questions on tactic to prevent HIV. Retrieved from http://www.nytimes.com/2011/10/11/health/11hiv.html?pagewanted=all&_r=1&
- Underhill, K., Operario, D., Skeer, M. R., Mimiaga, M. J., & Mayer, K. H. (2010). Packaging PrEP to prevent HIV: An integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. Journal of Acquired Immune Deficiency Syndromes 55(1), 8–13. doi:10.1097/QAI.0b013e3181e8efe4
- White, J. M., Mimiaga, M. M., Krakower, D. S., & Mayer, K. M. (2012). Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS, 26, 395–405.
![Supercharge Your Next Research Paper: Research and write your next paper with Jenni AI.]({"type":"image" , "src" : "/sda/112442/MPU-social-sciences.png"})